Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia.

ABSTRACT:

Background

As a malignancy of hematopoietic origin, the standard-of-care cytoreductive chemotherapy can not provide satisfactory treatment effect for patients with acute myeloid leukemia (AML). Immunotherapy has received increasing attention in leukemia treatment. However, the immunosuppressive microenvironment and low cancer immunogenicity of AML blasts create major obstacles to effectively inducing immune responses.

Methods

We developed an extracellular vesicle-based dual-delivery biosystem, which enhanced anti-AML immune responses by activating the immunogenicity of leukemia cells and relieving immunosuppression in AML allografted mice. Red blood cell-derived extracellular vesicles (REVs) were selected as delivery carriers due to the excellent biocompatibility. REVs were

SUBMITTER: Liu Y 

PROVIDER: S-EPMC12265820 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature